Promius Pharma LLC, a subsidiary of Dr. Reddy’s Laboratories, unveiled its new visual identity and corporate brand: The Power of Humans Being.
Omnicom Health Group announced that it is creating DDB Health, a dedicated, integrated healthcare network combining several U.S. and European professional healthcare agencies.
Tesaro Inc.’s experimental ovarian cancer drug niraparib met the main goal of prolonging survival in patients – without the disease worsening – in a late-stage trial.
The U.S. FDA is requesting additional data to support the safety and effectiveness of certain active ingredients used in topical consumer antiseptic rubs, including hand sanitizers, that are sold over-the-counter.
Irish drugmaker Shire Plc said a study testing an experimental drug to treat attention-deficit disorder met the main goal, bringing the drug one step closer to approval in the United States.
Lipocine Inc. said its oral testosterone replacement product did not get the approval in the United States, sending the drugmaker’s shares down 52 percent in premarket trading.
Esperion Therapeutics is on track to initiate global pivotal Phase 3 studies and global cardiovascular outcomes trial in fourth-quarter 2016 for Bempedoic Acid.
Aligned with global regulatory authorities on a consistent definition of statin intolerance
The U.S. Food and Drug Administration’s high-profile cancer drug director, Dr. Richard Pazdur, has been named head of a newly created Oncology Center of Excellence that will coordinate the review of all the agency’s cancer therapeutics.
A U.S. Food and Drug Administration Advisory Committee voted 12-11 that substantial evidence exists to establish that Jardiance (empagliflozin) reduces cardiovascular (CV) death in adults with type 2 diabetes and established CV disease. Jardiance, which is marketed by Boehringer Ingelheim and Eli Lilly, is the only oral T2D medicine shown in a clinical trial to reduce the risk of CV death.
White House spokesman Josh Earnest chided Republicans for failing to push forward with the president’s request for funding to combat the Zika virus and address an urgent public health crisis.
The U.S. Food and Drug Administration approved Gilead Sciences Inc.’s drug for treating chronic hepatitis C virus infection.
U.S. Senate Democrats called for bipartisan talks in the funding fight over Zika, saying a Republican proposal was “extreme and insufficient” to combat the virus and was full of “ideological poison pill riders.”
Smartphones, social media and crowdsourcing all have the potential to help people get faster, better treatment for heart attacks and strokes, according to the American Heart Association (AHA).
It’s official – Waltham, Massachusetts-based FORUM Pharmaceuticals will be shuttering its doors before the Fourth of July holiday.
Infinity Pharmaceuticals announced that North Chicago-based AbbVie chose to terminate its collaboration deal to develop and commercialize duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which are associated with malignant B-cells.
Australian company Mayne Pharma is acquiring 37 approved drugs and five products that have been filed with the U.S. FDA from Teva Pharmaceutical Industries and Allergan.
Pfizer Inc. will invest $350 million to build a biotech center in China, the latest in a series of moves by pharma industry giants to set up shop in the world’s no. 2 drugs market.
The U.S. Supreme Court rejected a bid to review a legal fight over the cancellation of a patent on a less-risky form of prenatal testing, in a case that has left many companies and trade groups worried that important discoveries may no longer qualify for patents.
After announcing that its Phase III clinical trial for algenpantucel-KL for resected pancreatic cancer failed in May, Ames, Iowa-based NewLink Genetics confirmed that it has laid off 87 employees.
AnGes MG Inc. announced its decision to amend the global development strategy of HGF Plasmid (AMG0001, Beperminogene Perplasmid) for the treatment of critical limb ischemia.